Company Overview - IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry, formed through the merger of IMS Health and Quintiles [11] - The company operates in over 100 countries and employs approximately 88,000 people [11] Investment Ratings - IQVIA is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A [12] - The Growth Style Score for IQVIA is B, indicating a forecasted year-over-year earnings growth of 6.4% for the current fiscal year [12] Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing to $11.84 per share [12] - IQVIA has an average earnings surprise of +1.7%, suggesting a positive trend in earnings performance [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, IQVIA is recommended as a potential investment opportunity for growth investors [13]

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

I am an independent trader and market analyst with a focused specialization in the micro-cap segment. My investment strategy combines technical analysis with the CAN SLIM methodology, pioneered by William O'Neil, to uncover high-growth companies that are often overlooked by mainstream analysts. I seek out emerging businesses showing strong financial momentum, rapid earnings growth, and signs of institutional interest—key indicators that often precede explosive stock moves. In addition to equities, I also ha ...

晨星投顾研讨会 围绕投顾服务与投资者场景化需求，结合实战经验与案例拆解，帮助从业者打造 一整套满足客户个性化需求的买方投顾方案，高效推动服务落地，赋能投资者成功！ 市场波动下，投资顾问如何确保客户账户具备抗风险能力？ 资产配置的分散性与风险适当性，正 成为守护客户财富的关键防线。 从诊断结果到配置优化的过渡路径不清晰，基于单品的分析结论难以转化为账户层面的可执行方 案...... 本次研讨会，晨星将携手投顾问们逐一破解以上难题，实现 全账户视角的持仓诊断与配置优化 晨星投顾研讨会后续主题预告 投顾场景的风险精细化识别与匹配 目标导向的个性化资产配置方案 然而现实中，账户管理面临诸多挑战： 客户账户分散难整合，依赖手工录入效率低； 风险诊断手段单一，依赖适当性评估或简单指标，持仓分析停留在单品层面，带有较强的预测性; 资产配置到个性化组合的落地实践 。 关于晨星 Morningstar, Inc.是全球目前最主要的投资研究机构之一，业务遍及北美、欧洲、澳洲及亚洲，为个人投资者、投资顾 问、基金管理公司、退休计划发起机构及私募领域的机构投资者等专业人士提供财经资讯、基金、股票的分析及评级， 并致力于发展具实用性、 ...

Forrester Research (FORR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 8, 2025 /PRNewswire/ - ...

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=155423&from=3  CLASS PERIOD: J ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. due to allegations of misleading statements and financial misrepresentations that have negatively impacted investors [3][5]. Group 1: Legal Investigation and Claims - Investors who suffered losses exceeding $50,000 in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - A federal securities class action has been filed against Fortrea, with a deadline of August 1, 2025, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting Transition Services Agreements (TSAs), leading to inflated EBITDA targets for 2025 [5]. - The company's public statements regarding its business model and financial prospects were claimed to be materially false and misleading [5]. Group 3: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model and a subsequent stock price drop of $2.73 per share (12.29%) to close at $19.48 [6]. - Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, after the company canceled two scheduled conferences, resulting in a stock price decline of $1.90 per share (8.06%) to close at $21.67 [7]. - Following the announcement of disappointing financial results on March 3, 2025, Fortrea's stock fell by $3.47 per share (25.05%) to close at $10.38, with the company acknowledging that its revenue and EBITDA expectations for 2025 were not met [8].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 表型可塑性 （ Phenotypic plasticity ） 是驱动癌症进展、转移和治疗耐药性的显著特征。胎儿样 （ Fetal-like ） 转录程序在促进细胞的可塑性状态方面的作用 日益受到关注，但由于现有培养模型的局限性，其作用仍难以研究。 2025 年 7 月 4 日，北京大学 邓宏魁 教授、 屈默龙 副研究员、北京大学首钢医院/北京大学肿瘤医院 顾晋 教授团队 （ 熊亮 、 徐莹 、 高兆亚 为共同第一作 者 ） 在 Cell Research 期刊发表了题为 ： A patient-derived organoid model captures fetal-like plasticity in colorectal cancer 的研究论文。 该研究开发了一种 化学成分明确的患者来源的类器官系统 （ CiPDO ） ，并用该类器官系统捕捉到了 结直肠癌 的 胎儿样可塑性 状态 。 在这项最新研究中，研究团队建立了一种 化学成分明确的患者来源的类器官系统 （ CiPDO ） ，培养条件是 EGF + CHIR99021 （Wnt激动剂） + LDN- 214 ...